Dismiss Notice
Links from our daily front page news are now being fed to this board. If you want to comment on any of the news articles, you can now do so there.

Daiichi to buy Accumetrics?

Discussion in 'Daiichi-Sankyo' started by Anonymous, Jul 1, 2010 at 11:09 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Everyone seems to know this about the CEO and VP but the investors. Someone needs to wake up the guys with the money!
     
  2. Anonymous

    Anonymous Guest

    What shall the guys with the money do? Let Accumetrics go bust and write off 68 Mn $? Now they still hope that somebody with lots of cash but no brain finally buys the company. Happened before in 2001 when Radiometer bought Accumetrics. Heard that Accumetrics has already been offered to everybody in the field at least twice, but the VCs have not given up yet. Roche seems to be their latest victim, however it should be impossible that this business case makes it through their due diligence.
     
  3. Anonymous

    Anonymous Guest

    Interesting product, but EXPENSIVE.
     
  4. Anonymous

    Anonymous Guest

    Already big problems with the program, most reps are afraid of the testing since it will also show hyper-responsiveness......plus, the Accumetrics guys seem to have all checked out. My guy is dying to get out of that company.
     
  5. Anonymous

    Anonymous Guest

    I think the Accumetrics guys are also afraid of the new Siemens PFA-100 plavix assay. Seems to be as fast and simple as Accumetrics, but 3 x lower test price and a much wider used instrument. This will kill Accumetrics IMHO.
     
  6. Anonymous

    Anonymous Guest

    Re: Daiichi to buy Accumetrics? - MORE FINANCING!

    Bingo!

    Another $7 million capital financing from the VCs...

    "The closure of this financing demonstrates continued and unwavering confidence from our investor base," said Timothy I. Still, President and CEO of Accumetrics. "We are excited to be positioned at the forefront of a major market shift in the healthcare sector where medical diagnostics will play a greater role in personalizing patient treatment."
     
  7. Anonymous

    Anonymous Guest

    Panic to bring in business at Accumetrics......The investors need to wake up to the Still/Chisolm scam. By the way, when are they releasing the machines that were used for the Lilly/Effient trial ....Hmmmmmmm//// Will Accumetrics tell their salespeople and other sales channels? I'm sick of the BS and lies.
     
  8. Anonymous

    Anonymous Guest

    Barely used machines are already hitting the market (450 that were used by DSI for the Effient trials) Accumetrics is turning their eyes, as Lilly has a financial stake in the sale of these machines. They were leased.
     
  9. Anonymous

    Anonymous Guest

    Sounds like another Glucowatch fiasco! Keep in mind that John G got us into that and he is going to be our next CEO! We are not better off than the Accumetrics people.
     
  10. Anonymous

    Anonymous Guest

    OMG! JG has a large vagina.
     
  11. Anonymous

    Anonymous Guest

  12. Anonymous

    Anonymous Guest

    It is absolutely a travesty how this company has blown this opportunity. Still and Chisolm are INCOMPETENT. Pilot program flop, Gravitas "need more research" waste of money, diluting sales channels and causing drastic drop in ASP, showing sales growth by increasing prices to dealers.....What a joke, good luck selling this company now.

    I agree with the previous post, whoever is putting money into this bomb hasn't done any real deep research lately.
     
  13. Anonymous

    Anonymous Guest

    450 machines available for sale with printers, with Accumetrics blessings. Bend over.
     
  14. Anonymous

    Anonymous Guest

    Accumetrics is in deep trouble

    Coming back from the AHA, my feeling is this company is in deep trouble:

    - the technology: no significant predictivity in both multicenter studies performed: IMO people underestimate that this is the really sad message of the GRAVITAS data, even worse than the lack of benefit in the high clopidogrel group. See slide 19 in: http://sciencenews.myamericanheart.org/pdfs/GRAVITAS_pslides.pdf
    And also slide 28 in:
    http://spo.escardio.org/eslides/view.aspx?eevtid=33&fp=4989
    Failure to show any significant predictivity in two multi-center studies with 1001 patients (Verifrenchy) and 1691 patients (Gravitas observational substudy) means that the technology is not able to do what it is supposed to do: to identify patients at significantly increased risk.

    - the management: The accumetrics management seems to suffer from an inverse Midas syndrome: everything they do seems to fail. Also you meet all the time people that have negative stories about them to tell (or posts in this and other forums), and nobody who seems to be positive about them - obviously except from the investors.

    - financial data: 05-2003: series A financing $1.3 million, 07-2004: series B financing $13.5 million, 02-2006: series C financing $8.25 million, 02-2008: series D financing $28.8 million, 10-2009: series E financing $16.6 million, additional $7 million announced in 9-2010.
    $75.5 million in VC???
    Is this a company or a Ponzi scheme?
    $52.4 million since 2008, which is approximatelly $1.5 million per MONTH.
    They donĀ“t need a buyer, they need a bailout IMO. Perhaps Obama can help.
     
  15. Anonymous

    Anonymous Guest